文献速递妇科

基于分子整合风险档案决定子宫内膜癌辅助放疗:PORTEC-4a试验 pilot 阶段评估

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
PubMed 文献 · Gynecol Oncol · 2018-08-03

PORTEC-4a试验针对高危中间型子宫内膜癌患者,比较基于分子整合风险档案的个体化辅助治疗与标准辅助阴道近距离放疗。pilot阶段纳入前50例患者,评估患者接受度和病理物流可行性,结果显示35%的合格女性同意参与,风险档案确定平均需10.2天(1-23天),32例中5例(15.6%)病理审查超过2周,试验设计可行。

要点

  • 145例合格女性中50例(35%)签署知情同意,各中心入组率0-57%。
  • 不参与最常见原因为不愿参加任何试验(43.2%)和不愿承担无辅助治疗风险(32.6%)。
  • 随机化至分子整合风险档案确定平均10.2天(1-23天),32例中5例(15.6%)病理审查超过2周。

核心结论

  • PORTEC-4a试验设计被证明可行,患者接受度满意,分子整合风险档案确定的工作流程得到优化。
  • PORTEC-4a是首个研究使用分子整合风险档案决定子宫内膜癌辅助治疗的随机试验。

研究设计与样本

  • PORTEC-4a是一项随机试验,比较高危中间型子宫内膜癌基于分子整合风险档案的个体化辅助治疗与标准辅助治疗(阴道近距离放疗)。
  • pilot阶段纳入前50例入组患者,评估患者接受度(分析参与中心筛查日志)和风险档案在2周内确定的物流可行性(分析病理数据库)。

主要发现

  • 第一年13个中心共145例合格女性被告知试验,其中50例(35%)提供知情同意,各中心入组率范围为0-57%。
  • 不参与最常见原因为不愿参加任何试验(43.2%)和不愿冒无辅助治疗风险(32.6%)。
  • 病理数据库分析显示随机化至分子整合风险档案确定平均时间10.2天(1-23天),32例中5例(15.6%)病理审查耗时超过2周。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a randomized trial for women with high-intermediate risk endometrial cancer (EC), comparing individualized adjuvant treatment based on a molecular-integrated risk profile to standard adjuvant treatment; vaginal brachytherapy. To evaluate patient acceptability and pathology logistics of determining the risk profile, a pilot phase was included in the study. METHODS: PORTEC-4a is ongoing and the first 50 patients enrolled were included in the pilot phase. Primary endpoints of the pilot phase were patient acceptance, evaluated by analyzing the screening logs of the participating centers, and logistical feasibility of determination of the risk profile within 2 weeks, evaluated by analyzing the pathology database. RESULTS: In the first year, 145 eligible women were informed about the trial at 13 centers, of whom 50 (35%) provided informed consent. Patient accrual ranged from 0 to 57% per center. Most common reasons for not participating were: not willing to participate in any trial (43.2%) and not willing to risk receiving no adjuvant treatment (32.6%). Analysis of the pathology database showed an average time between randomization and determination of the molecular-integrated risk profile of 10.2 days (1-23 days). In 5 of the 32 patients (15.6%), pathology review took >2 weeks. CONCLUSIONS: The PORTEC-4a trial design was proven feasible with a satisfactory patient acceptance rate and an optimized workflow of the determination of the molecular-integrated risk profile. PORTEC-4a is the first randomized trial to investigate use of a molecular-integrated risk profile to determine adjuvant treatment in EC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wortman BG, Bosse T, Nout RA, et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol. 2018. PMID: 30078506. doi:10.1016/j.ygyno.2018.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。